Balancing hope and hesitation: A closer look at Tofersen approval for ALS
Niamh Walker reports on a recent, controversial decision by the FDA to approve Tofersen for ALS treatment.
drug development
Continue reading
Traditional medicine: From ancient remedies to evidence-based healthcare
Adèle Bouyer explores the efficacy and challenges of traditional, complementary, and integrative medicine in modern healthcare.
PROTACs: Targeting breakdown of specific proteins to treat diseases
Felicites Rapon explores the advantages of PROTACs over small molecule inhibitors in addressing cancer treatment and drug resistance.
Labs-on-a-chip: How liquid has revolutionised science
Marianna Birkitt examines the multifaceted applications of microfluidics in biological research, ethical drug testing, and space exploration.
The science of skinny: Ozempic reinforces the obsession with thinness
Isabelle Goodall-Summers explores the off-label use of Ozempic for weight loss, highlighting potential societal implications.
The legacy of a girl who inspired a “holy grail” cancer-killing pill
Niamh Walker reports on the recent development of AOH1996, a pill targeting cancerous cells, offering a new approach to cancer treatment.
Senolytics and dementia—The war against ageing
Lily Massey explores the potential of senolytics to combat age-related diseases, possibly improving the quality of human life in later years.
Ringing in the brain: Tinnitus and the nervous system
Jamie Adams reviews what we know about tinnitus, and options for treating this mysterious medical condition.
Are animal models still relevant to drug development?
Adèle Bouyer reviews how a recent change in FDA regulation may herald a decline in animal testing, in the face of new alternative models.
Is the blood-brain barrier a barrier to medical progress?
Sophie Beaumont reviews research into how the blood-brain barrier protects the brain, and poses challenges for delivery of medical treatment.
- 1
- 2